Previous Article | Next Article ![]()
Journal of Virology, January 1999, p. 436-443, Vol. 73, No. 1
Australian Red Cross Blood Service-NSW,
Sydney, New South Wales, Australia1;
Institute of Molecular Medicine, Nuffield Department of
Medicine, Oxford, United Kingdom2; and
Aaron Diamond AIDS Research Center, The Rockefeller
University, New York, New York3
Received 13 July 1998/Accepted 21 September 1998
Proposals for the use of live attenuated human immunodeficiency
virus (HIV) type 1 (HIV-1) as a vaccine candidate in humans have been
based on the protection afforded by attenuated simian immunodeficiency
virus in the macaque model. Although it is not yet known if this
strategy could succeed in humans, a study of the Sydney Blood Bank
Cohort (SBBC), infected with an attenuated HIV-1 quasispecies with
natural nef and nef/long terminal repeat deletions for up to 17 years, could provide insights into the long-term
immunological consequences of living with an attenuated HIV-1
infection. In this study, HIV-specific cytoxic T-lymphocyte (CTL)
responses in an SBBC donor and six recipients were examined over a
3-year period with enzyme-linked immunospot, tetrameric complex
binding, direct CTL lysis, and CTL precursor level techniques. Strong
HIV-specific CTL responses were detected in four of seven patients,
including one patient with an undetectable viral load. Two of seven
patients had weak CTL responses, and in one recipient, no HIV-specific
CTLs were detected. High levels of circulating effector and memory
HIV-specific CTLs can be maintained for prolonged periods in these
patients despite very low viral loads.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Strong Human Immunodeficiency Virus (HIV)-Specific
Cytotoxic T-Lymphocyte Activity in Sydney Blood Bank Cohort Patients
Infected with nef-Defective HIV Type 1
*
Corresponding author. Mailing address: Australian Red
Cross Blood Service-NSW, 153 Clarence St., Sydney, NSW 2000, Australia. Phone: 61 2 9229 4557. Fax: 61 2 9229 4521. E-mail:
wdyer{at}arcbs.redcross.org.au.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|